Clonazepam has been used in the treatment of burning mouth syndrome (BMS) for several decades.
Clonazepam is
used to treat pain disorders and seizures. Oral pain sensations can be
effectively treated using clonazepam according to the literature studies and
the statistical analysis of the results obtained from this present study.
Clonazepam has
been used in the treatment of burning mouth syndrome (BMS) for several decades.
We conducted a meta-analysis to investigate the efficacy of clonazepam in the
treatment of BMS.
We conducted a
search of the PubMed, MEDLINE, EMBASE, Web of Science (TS), and the Cochrane
Library databases for relevant studies that met our eligibility criteria (up to
September 22, 2015). Statistical analyses were conducted using RevMan 5.2 and
STATA 11.0 software.
Three randomized
controlled trials (RCTs) and two high-quality case–control studies involving
195 BMS patients were selected for this study. Our results show that clonazepam
can reduce the oral pain sensation in patients with BMS (WMD: −3.72, 95% CI:
−4.57, −2.86; P < 0.05; for all five studies). A positive therapeutic effect
was demonstrated for both short-term (≤10 weeks) application (WMD: −1.44, 95%
CI: −2.06, −0.82; P < 0.05) and long-term (>10 weeks) application (WMD:
−4.50, 95% CI: −4.98, −4.03; P < 0.05). Both topical (WMD: −1.50, 95% CI:
−2.14, −0.85; P < 0.05) and systemic (WMD: −3.81, 95% CI: −4.63, −2.98; P
< 0.05) administration of clonazepam were confirmed to be effective.
Clonazepam is
effective in inducing symptom remission in patients with BMS.
Oral Dis. 2015 Dec 17
Efficacy evaluation of clonazepam for symptom remission in burning mouth syndrome: a meta-analysis
Y Cui et al.
Comments (0)